Diaccurate

Evexta Bio (ex-Diaccurate) is a clinical stage biotech developing a next generation precision cancer therapies to cure patients from incurable diseases. Its most advanced compound DIACC3010 optimally inhibits S6K, a kinase involved in many cancers as metastatic breast cancer, glioblastoma or gastric cancer. Licensed from Merck KGaA, it has demonstrated promising clinical efficacy signals in Phase I and will enter Phase II in 2023. Its second project DIACC2010 refers to the development of the only molecule known to inhibit KIF20A (a kinesin involved in the proliferation of cancer cells) while non toxic for normal cells. Its mode of action makes it a privileged candidate to become a new payload for the ADCs (Antibody Drug Conjugates) which is a new technology presently revolutionizing cancer treatment. Evexta Bio relies on a experienced management team and is supported by an international Scientific and Medical Board composed by world first class experts.